Evidence map›Paper›PMID 34997203›Full record

ArticleScientific reports2022

Amikacin potentiator activity of zinc complexed to a pyrithione derivative with enhanced solubility.

Jesus Magallon, Peter Vu, Craig Reeves, Stella Kwan, Kimberly Phan, Crista L Oakley-Havens, Kenneth Rocha, Veronica Jimenez, María Soledad Ramirez, Marcelo E Tolmasky

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jesus MagallonCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA.
Peter VuCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA.
Craig ReevesCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA.
Stella KwanCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA.
Kimberly PhanCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA.
Crista L Oakley-HavensCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA.
Kenneth RochaCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA.
Veronica JimenezCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA.ORCID 0000-0002-0744-8137
María Soledad RamirezCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA.ORCID 0000-0002-9904-7890
Marcelo E TolmaskyCenter for Applied Biotechnology Studies, Department of Biological Science, California State University Fullerton, 800 N State College Boulevard, Fullerton, CA, 92831-3599, USA. mtolmasky@fullerton.edu.ORCID 0000-0002-6298-7811
California State University, Fullerton · US

Funding

DEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8M
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter sppSC3GM125556 · NIGMS · CALIFORNIA STATE UNIVERSITY FULLERTON · PI RAMIREZ, MARIA SOLEDAD · 2018 to 2025
$851k
NIAID NIH HHS R15 AI047115NIGMS NIH HHS SC3 GM125556
6 · The paper itself

Abstract

Resistance to amikacin in Gram-negatives is usually mediated by the 6'-N-acetyltransferase type Ib [AAC(6')-Ib], which catalyzes the transfer of an acetyl group from acetyl CoA to the 6' position of the antibiotic molecule. A path to continue the effective use of amikacin against resistant infections is to combine it with inhibitors of the inactivating reaction. We have recently observed that addition of Zn

Indexed as

AcetyltransferasesAcinetobacter baumanniiAmikacinAnti-Bacterial AgentsDrug Resistance, BacterialEnzyme InhibitorsKlebsiella pneumoniaeMicrobial ViabilityOrganometallic CompoundsPyridinesSolubilityTime FactorsAcetyltransferasesAmikacinaminoglycoside N(6')-acetyltransferaseAnti-Bacterial AgentsEnzyme InhibitorsOrganometallic CompoundsPyridinespyrithione zinc

Identifiers

PMID34997203
PMCPMC8741805
OpenAlexW4225975951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.